David Schodin is the Chief Strategy Officer (CSO) for MTI. He has worked extensively in corporate development, partnership and alliance formation and execution, intellectual property strategy and licensing, and biotechnology evaluation in the diagnostics and pharmaceutical industries. David earned a JD (summa cum laude) from Chicago-Kent School of law and holds a PhD in biochemistry from the University of Illinois at Urbana-Champaign.
He is a proven corporate development leader with a decade of experience in each of corporate development, patent and commercial law and molecular biology research.
David comes to us from Abbott Molecular where he was the Director, Business Development & Licensing for several years.